Clinical Trial Update: A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating erlotinib in patients with advanced or metastatic breast cancer during or after chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED